insights_auto
Mengapa MANKIND turun 3,07%?
Pelajari Lebih Lanjutchevron_right
MANKIND:NSE
Mankind Pharma Ltd
Rs 2.275,50
arrow_downward
-3,07%(-72,10) 1 HR
16 Okt, 15.30.00 GMT+5.30 · INR
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk MANKIND...
Pembukaan
Rs 2.349,90
Tinggi
Rs 2.354,40
Rendah
Rs 2.268,70
Kapitalisasi pasar
937,40Â M
Volume rata-rata
483,95Â rb
Volume
889,73Â rb
Rasio P/E
46,04
Harga tinggi dalam 52 minggu terakhir
Rs 2.642,00
Harga rendah dalam 52 minggu terakhir
Rs 1.909,70
EPS
Rs 49,42
Jumlah karyawan
20Â rb
Pembukaan
Rs 2.349,90
Tinggi
Rs 2.354,40
Rendah
Rs 2.268,70
Kapitalisasi pasar
937,40Â M
Volume rata-rata
483,95Â rb
Volume
889,73Â rb
Rasio P/E
46,04
Harga tinggi dalam 52 minggu terakhir
Rs 2.642,00
Harga rendah dalam 52 minggu terakhir
Rs 1.909,70
EPS
Rs 49,42
Jumlah karyawan
20Â rb
Artikel berita
Dari sumber web dan partner berita
The Pharma Letter
·
11 jam yang lalu
Lakefront sells CAR-T programs as Mankind agrees Armed Cell investment
Profil
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
Tentang Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Karyawan20,5Â rb
Didirikan1991
Kantor Pusat-
Sektor-
Situsmankindpharma.com